Reviewing Oncobiologics (OTLK) & Its Competitors

Oncobiologics (NASDAQ:OTLK) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Oncobiologics to similar companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Risk & Volatility

Oncobiologics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Oncobiologics’ peers have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Oncobiologics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Oncobiologics Competitors	-9,046.59%	-199.78%	-30.61%

Earnings and Valuation

This table compares Oncobiologics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncobiologics	$1.35 million	-$62.42 million	-0.57
Oncobiologics Competitors	$691.13 million	$10.43 million	-15.00

Oncobiologics’ peers have higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Oncobiologics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Oncobiologics Competitors	9827	15118	45430	1583	2.54

Oncobiologics presently has a consensus target price of $5.20, suggesting a potential upside of 1,091.57%. As a group, “Biotechnology” companies have a potential upside of 102.59%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than its peers.

Insider and Institutional Ownership

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Oncobiologics peers beat Oncobiologics on 9 of the 12 factors compared.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.